This 9 SpaceX Stock Has Crazy Potential

Financial Freedom
10 followers
#finance
#financement
Time Stamps
0:00 INTRO
1:02 SPACEX OPPORTUNITY
4:28 THEIR SUPPLY CHAIN
10:03 STOCK FIVE
10:49 STOCK FOUR
11:24 STOCK THREE
12:02 STOCK TWO
13:03 STOCK ONE
13:35 UNDERVALUED STILL?
16:18 SPONSOR
Folks, the SpaceX IPO is coming and this is expected to be the biggest IPO in stock market
history. And while everyone is asking how to buy SpaceX directly, well, the smart money is
continuing to pile into SpaceX adjacent stocks. In today's video, I'm going to walk you through
the entire SpaceX supply chain, every category of supplier they have and where the money flows.
We're going to break down the SpaceX adjacent stocks that are seeing the biggest Wall Street
buyers. And then at the end, I'm going to give you one stock that I believe is significantly
undervalued. A stock that has barely rerated at all, despite this massive IPO and despite the
fact that it is a supplier to SpaceX. I'll break down my case for it and I'll let you be the judge.
And then it will be time for our sponsored segment on Medicus Pharma, ticker symbol MDCX,
on the NASDAQ. They are developing one of the first microneedle delivered chemotherapy
approaches for basal cell carcinoma, the single most common form of cancer in the USA.
I'll present the company and why you may want to take a look at it. And as always,
if you're the one taking the ultimate risk, you got to be the one doing the ultimate frisk.
Always do your own due diligence on all ideas presented.
Okay, so there are two major themes that you need to understand heading into the SpaceX IPO.
So number one, the SpaceX IPO is going to flood potentially trillions and trillions of dollars
into the space stock sector. It's already flooded a lot even before the IPO. It's going to flood
even more long term. And with SpaceX having all this capitalization, well, you're going to see a
lot of competitors that are private that can work with SpaceX start IPO-ing as well. And a lot of
companies that are already publicly traded are going to continue to see massive valuation
increases. So that's the first part you have to understand, which is the massive flood of capital
going into the space industry. The second part you have to understand is that the bigger opportunity
and perhaps the more risky, if you don't understand that this is going on, is the story value.
So when it comes to these kind of IPOs, the story value is what really creates the most wealth over
the short term. In the long term, the story value has to be fulfilled with actual fundamental value
creation. But in the short term, there's the story that you're selling to the people. Elon Musk is
one of the best story sellers on the planet, probably in world history. Not only is he great
at actual execution, but even though he's great at execution, he's able to sell a story that's like
five times even better than his amazing execution. But you have to understand how these two come
together because they're not only going to create massive opportunities, but they're also going to
create big pitfalls if you don't follow. You need to understand that there's a difference between
the fundamental value of a company and the story value. Wall Street makes their money on story
value. And you can make your money on story value too, but you could also lose a lot of money on it.
SpaceX is going public at potentially a $2 trillion valuation. That number is so big that
it's forcing every fund manager, every analyst, every retail trader, your neighbor next door to
ask one question. And that question is, what else can I own that will benefit from this?
And when they go looking for those stocks, they're not running discounted cashflow models.
They're not looking at gross margins. They're looking for proximity to the story,
proximity to SpaceX. Right now and heading into IPO, basically anything close to the
SpaceX narrative is getting bid up. Suppliers, competitors, adjacent technology plays,
even unrelated satellite stocks. Wall Street does not care if a stock price is justified or
unjustified. Wall Street is interested in making money. It's not interested in valuing a company
properly and only buying it when it's undervalued. It's interested in getting the stock low and
selling when it's high. That's why during some narrative cycles, stocks will go down 70% to 80%,
even though the underlying fundamentals might have only crashed 5%. And alternatively,
why an entire sector like the space sector might go up hundreds of percentage points
just because you have a massive IPO coming for one of the leading stocks in that sector.
You can ignore these trends or you can benefit from them. It's up to you,
but you have to understand what's going on here because you have the fundamentals
and then you have the massive story potential. Those who do well long term understand how to put
both the story potential and the fundamentals into their broader investment thesis.
So why am I telling you this? Well, because this is the exact playbook that Wall Street is
following right now. They're buy, buy, buying into stock after stock that is adjacent to the SpaceX
IPO. And almost all of them are going to see a big dip after the SpaceX IPO as these institutions
start taking their profits. You have the anticipatory run and then you have the post
crash and then long term value starts shining through. And that's probably true for the SpaceX
IPO itself as well. Now, that being said, there's still some areas of the market that have a ton
more opportunity heading into this IPO for folks who are diligent and understand risk management
and want to actually take advantage of this hype instead of let the hype take advantage of you.
So let's just start with an overview of the SpaceX supply chain here and where the money's
actually flowing. So SpaceX is not just one business. It's effectively three. There's the
launch business, which is Falcon 9, Falcon Heavy, Starship. There's the constellation business,
Starlink, and the 7,000 plus satellites that are in orbit as we speak. And then there's the
emerging defense and space services business, which is Starshield, government contracts,
and lunar missions. Each of these requires a completely different supply chain, as you might
imagine. And let me walk you through each of the major categories here. So category one,
launch hardware encompasses everything that goes into building the rockets themselves.
Aluminum, lithium alloy body, stainless steel for Starship, titanium for engines,
advanced composites for fairings. The big consumables, liquid oxygen, kerosene, methane.
SpaceX is actually one of the largest industrial gas customers in North America. Industrial gas
suppliers like Air Liquid, Lind, and Praxair quietly benefit from every single launch,
and they get massive bulk orders from SpaceX. And then there are specific alloys. Companies like ATI
Inc. and Hanes International make the high temperature metals SpaceX needs for engine
bells and combustion chambers. Category two, satellite manufacturing. Oof, does this cost a
lot of money? And is this a high margin business for those supplying? So each Starlink satellite
has thousands of components. The major buckets, well, first solar arrays to power satellites.
Red wire, which we're going to talk about later, is a key player in this. Then you have propulsion
systems. These are hull effect thrusters that let satellites maneuver in orbit. Companies like
Aerojet Rocketdyne historically dominated the space, but there are some new players emerging
like Phase Four and Orbion, which have entered this market as well. Then you have star trackers
and altitude control. These are the sensors that tell a satellite which way it's pointing.
Honeywell, Collins Aerospace, and Redwire all play here. Onboard processors and radiation-hardened
chips. These are silicon designed to survive cosmic radiation. BAE Systems makes this.
Microchip Technology makes it. And Texas Instruments have specialty product lines
for this specifically. Very, very lucrative for these businesses. Then you have inter-satellite
links, how Starlink satellites actually talk to each other. You have Maneric,
which Rocket Lab just acquired. That's one of the main leaders here.
Okay. Category three, ground infrastructure. So you cannot have a satellite constellation
without massive ground gateways that talk to the satellites. Each gateway requires high
power amplifiers, and that's a company called Filtronic who handles that. Filtronic's gallium,
nitride, E-band chips, phased array antennas, RF filters, modems, back hull, networking gear from
Juniper. Massive amounts of fiber connectivity. Very lucrative. There are over 150 Starlink
gateway sites globally and growing. Each one of them, as you might expect, costs many, many,
many millions of dollars to build out. Okay. Category four, chips and compute. You guys are
probably familiar with this area, but SpaceX is one of the most chip-intensive companies on earth
as a fact. You've got rocket guidance computers that handle re-entry and landing,
satellite onboard compute that processes data in orbit, ground station compute that handles signal
processing. And now with the Tesla AI5 partnership and TerraFab project, SpaceX is moving deeper into
custom silicon. Behind all of that, you have Taiwan semiconductor manufacturing chips, Amcor
packaging them. Companies like Marvel Analog Devices and Texas Instruments supply the analog
and RF chips. Power management IC suppliers like Monolithic Power benefit from every gateway and
every satellite. Category five, and stick with me here. It's important that you know the supply
chain. Category five is connectivity and customer hardware. So the Starlink dish you'd put on your
house isn't just a piece of plastic. No, no, no. It's a phased array antenna with hundreds of
individual transceivers. The kit includes routers, power supplies, mounting hardware, custom connectors.
SpaceX manufactures most of the critical components in house, but the supply chain for raw silicon,
PCP, substrates, and assembly is global. And there's a lot of orders going out for that. Now,
in terms of category six, you've got specialized material. This one's less obvious, but it's very
important. Heat shield, tiles for Starship use silicon composites, cryogenic insulation for fuel
tanks, specialty paints and thermal coatings, aerogel insulation, nickel alloys for engine
internals. Companies in this space are Matron, Masterspace, and various specialty chemical firms.
They're some of the biggest beneficiaries. Finally, you have category number seven,
which is software, cybersecurity, and data. So SpaceX runs on enormous amounts of code,
as you might imagine, real-time guidance systems, constellation management software,
cybersecurity for ground stations and uplinks, data routing and customer management platforms,
so on and so forth. Names like Palantir have explored, Space Data Partnerships, Cloudfaring
AWS provide ground side networking and compute, and cybersecurity firms benefit as government
Starshield contracts start ramping up in a beautiful way. So why exactly does all this
matter, Charlie? Well, when the SpaceX IPO drops, every single one of these supply chain categories
gets analyst attention, and Wall Street is going to publish report after report. You're going to
see it all over the mainstream media. Funds are going to launch and have already launched many,
many SpaceX-themed ETFs, which means that more and more buying pressure is going to head to many of
these names. And the names that have the cleanest, most documented exposure, like the ones we're
talking about in today's video, are going to be the ones that are getting re-rated first.
Next, I want to talk about five SpaceX stocks that are all getting re-rated massively right now and
are kind of centrally located in the supply chain setup. And actually, a lot of these were on our
previous SpaceX stock video that we posted like a little bit over a month ago. I need to break
down these five before we get onto the main entree, which is one that is still very, very much
undervalued, not just based on story potential, but based on the actual fundamental value behind
it. All the stocks we're about to talk about have a lot more story potential to run, but you could
argue they're also very much fundamentally overvalued. However, the one at the end both
has a lot more story potential and a lot more fundamental potential in my view, and I'll break
down why. So let's start with number five. So Intuitive Machines, LUNR. So Intuitive Machines
builds lunar landers and surface delivery systems for NASA's Artemis program. They literally land
hardware on the moon. Why is it running? Well, two reasons. First, they ride SpaceX rockets to the
moon, pure ecosystem play. Second, and this is the bigger story, management just guided to $900
million to $1 billion in 2026 revenue. That's nearly 5X the $210 million they reported in 2025.
They've also got a backlog approaching $943 million from NASA's commercial lunar payload
services contracts and defense awards. The kicker is they're guiding to positive adjusted
EBITDA in 2026. That would make them one of the very first non-SpaceX commercial space companies
to actually reach that milestone. NASA's recent $20 billion moon base announcement is a direct
tailwind here. Okay. Number four, AST SpaceMobile, ASTS. So AST SpaceMobile is building something
nobody else has pulled off, a space-based cellular broadband network that works directly with
standard unmodified smartphones. No special equipment, no satellite phone. Your normal
iPhone connects directly to their satellites. Revenue exploded from $4.4 million in 2024 to
$20.9 million in 2025. That was a 1500% jump. They're guiding $150 million to $200 million for
2026 with $1.2 billion in contracted revenue. AT&T, Verizon, Vodafone, Orange, TELUS, every
major telecom company on earth has signed up here. The narrative is very, very clean.
Number three, Planet Labs PL. So Planet Labs operates the largest fleet of earth imaging
satellites in the world. Daily global imagery, they scan the entire planet every single day.
It's out of this world. Fiscal 2026 revenue hit $307.7 million, up 26% year over year. Backlog
jumped 79% to $900 million. They've achieved four consecutive quarters of adjusted EBITDA
profitability and 98% of their revenue is recurring annual contract value. That's high quality,
predictable software-like revenue. Very, very beautiful. We love predictable revenue.
The SpaceX connection here, well, Planet Labs uses SpaceX Falcon 9 rockets to launch
their satellite's direct ecosystem participant here.
Number two, Filtronic. This one's been running a lot as of late and it's quite special and it's
probably one that you haven't heard of if you're an American investor because it trades on other
exchanges. But this stock actually trades on the OTC exchange as FLTCF and then on the London Stock
Exchange under ticker symbol FTC. Filtronic is the British company that makes the high power
E-band amplifiers for Starlink ground stations without these chips. Starlink doesn't work the
way it's supposed to. And SpaceX has literally filled their entire factory with orders if you
look at the reporting. Now, here's the thing with this company. SpaceX has actual equity exposure
to Filtronic. This is through a strategic partnership signed in April 2024 and it was
expanded in March 2025. SpaceX holds warrants for up to 15% of Filtronic share capital with roughly
10% already vested. So SpaceX is essentially a 10% shareholder in Filtronic. In August 2025,
they signed their largest ever single contract, a 47.3 million pound deal with SpaceX worth about
62.5 million US for next generation GAN E-band products. The first production units are supposed
to ship in fiscal 2027. Okay, number one, Rocket Lab RKLB. So Rocket Lab is the closest publicly
traded SpaceX comparable, period. They built these small launch rockets, Electron, and they're
developing Neutron, not to be confused with Jimmy Neutron, but Neutron, a medium lift reusable
rocket designed to compete directly with Falcon 9. Revenue hit a record 602 million in 2025,
up 38% year over year. They've got a $1.85 billion backlog, just acquired Mineric to add
laser optical communications to their portfolio, just announced a partnership related to Meta
Now it's time for the main entree, the stock that I still believe is very, very undervalued.
So again, with all the companies on this list, there's still some story premium left to be
factored in, of course, because this IPO can drive so much hype and euphoria into the sector.
However, there's one name that has all the same pieces, direct SpaceX connection,
real revenue, growing backlog, defense exposure, but it has not really had its monster move yet.
That stock is RedWire Corporation, RDW, let me present the case for it. So RedWire built something
called the Rollout Solar Array, ROSA for short. In plain English, traditional solar panels on
satellites are these big rigid hinge contraptions that fold out like accordions. Heavy, complex,
lots of moving parts. ROSA, ROSA is very different. ROSA McRosie is a very different beast.
It rolls up like a yoga mat, packs into a small canister, launches into space and unrolls itself
using stored strain energy. There's no motors needed, which means it's going to be lighter,
it's going to be stronger, and it's going to be a lot smaller. Here's the direct connection. So
RedWire's ROSA technology has flown on multiple SpaceX Dragon cargo missions to the International
Space Station, for specific SpaceX 22, SpaceX 26, and SpaceX 28. The iROSA wings powering a
huge chunk of the ISS today were rolled up inside SpaceX Dragon trunks and lifted to orbit on SpaceX
Falcon 9 rockets. So this is a company that literally helps SpaceX power its missions.
They also make star trackers, sun sensors, antennas, radio frequency payloads,
deployable structures, and even drones. About 1,300 employees across the US and Europe,
and their cameras were on the Orion Artemis 2 spacecraft that just did the mission last month.
They also just won a European Space Agency Hammerhead spacecraft contract for Quantum
Secure Satellite Communications. They're supplying solar arrays to Axiom Space for the first commercial
space station module. And on the defense side, over 20 million in Q1 2026 follow on orders
from the US Navy and Marine Corps for their Stalker drone systems.
Now let's compare the valuation to some of the competitors here. Rocket Lab trades at roughly
75X trailing revenue. Planet Labs at 43X. Lunar at 14X. ASTS at 350X. RedWire trades at about 5.5X
trailing revenue. That's not because the business is worse. It's because the market hasn't really
re-rated it at all yet. It hasn't had any of the story premium baked in, and it's barely
had any fundamental premium baked in. This is a company that's got documented SpaceX exposure,
multi-mission Artemis contracts, a growing defense business, a record backlog,
it's guiding to 41% revenue growth, and it's still trading in the lower half of its 52-week range.
I believe that when the SpaceX IPO drops in June and money rotates into anything with a SpaceX
connection, well, it's going to be very hard to believe that RWD, that RDW, isn't trading much,
much higher. So that's my take here, and that's the asymmetric setup that I see on this stock,
especially when comping to its competitors and its adjacent players.
Anyways, now let's move on to our sponsored segment. And today's sponsored segment is on
the NASDAQ. They're developing what could be one of the first microneedle-delivered
chemotherapy approaches for basal cell carcinoma, the single most common form of
cancer in the entire United States. So every year, millions of Americans receive a cancer
diagnosis that doesn't threaten their life, but the treatment leaves a lasting mark.
That's the reality for patients with basal cell carcinoma, the most common form of cancer in the
United States. The standard of care works, but it involves surgery. Basal cell carcinoma, or BCC,
is not just the most common skin cancer, it's the single most common form of cancer in the entire
US, with an estimated 3.6 million cases diagnosed every year. Nearly one in five Americans will
develop it over a lifetime, and the incidence rate has been increasing at over 10% annually
in white populations. The good news, it's rarely fatal. However, the bad news is that the standard
of treatment is Mohs surgery, a procedure where doctors cut the cancer out of the skin layer by
layer under a microscope. The challenges with that current standard of care are significant.
Cure rates are above 95%, but the procedure is invasive and leaves visible scarring. When tumors
appear on the face, nose, or eyelids, cosmetic disfigurement becomes a serious concern.
Elderly patients who cannot tolerate surgery also have very limited alternatives. Patients
with Gorlin syndrome, who develop hundreds of tumors over their lifetime, face a near-impossible
surgical burden, and the estimated market opportunity for BCC treatment is approximately
$2 billion. For a cancer that rarely kills, the current treatment carries consequences that many
patients and physicians would rather avoid. That gap represents a meaningful, unmet need.
Medicus Pharma developed a product called Skinject, built around a straightforward concept.
It's a patented, dissolvable microneedle patch loaded with doxorubicin, a well-established
chemotherapy agent. The patch is placed directly on the tumor, the microneedles
dissolve into the skin, and the drug is delivered straight to the cancer cells. No surgery,
no systemic exposure, no operating room required.
The clinical data gathered so far includes Phase 1 completed in March of 2021, meaning its primary
endpoint of safety and tolerability, no dose-limiting toxicities, and no serious adverse
events across all 13 Phase 1 patients. Six out of 13 Phase 1 participants achieved complete
responses, meaning cancer was histologically absent upon tissue examination. Phase 2 is a
randomized, double-blind placebo-controlled trial across nine U.S. clinical sites. Enrollment of
90 patients was completed in December of 2025, and the top-line results reported on March 5,
2026 showed 73% clinical clearance and 40% histological clearance in the 200-mcg cohort
at day 57, with an 80% overall response rate, representing a clear separation from the 38%
clinical clearance observed in the device-only control arm. The full clinical study report is
expected in Q2 of 2026, and the company has described the dataset as decision-grade evidence
to support an end-of-Phase 2 meeting with the FDA and accelerate partnering readiness.
Now, in terms of regulatory and partnership progress, beyond the clinical data,
Medicus has been building out its regulatory and commercial infrastructure.
Several developments are worth noting. The FDA has supported the 505B2 regulatory pathway for
Skinject, which could accelerate development timelines and reduce costs compared to a
traditional new drug application. An end-of-Phase 2 meeting with the FDA is planned for the first
half of 2026 to establish the Phase 3 pathway. The company has a strategic collaboration with
Gorlin Syndrome Alliance to pursue an expanded access program, given patients with this rare
genetic condition supervised access to Skinject. An application has been submitted under the FDA
Commissioner's National Priority Voucher Program, which could fast-track the review
timeline. Clinical trials are being expanded internationally, with studies underway in the
UK and UAE. There is a second pipeline asset as well. In September 2025, the company completed
the acquisition of Antev Limited, a UK-based clinical-stage biotech-developing Tevrlex
next-generation GnRH antagonist targeting advanced prostate cancer. Approximately 300,000 to 500,000
men in the US are living with advanced prostate cancer, and the standard treatment is Androgen
Deprivation Therapy, or ADT, which lowers testosterone to slow disease progression.
Existing GnRH agonists, a common class of ADT drugs, significantly increase cardiovascular risk.
Cardiovascular disease accounts for roughly 30% of all non-cancer deaths in prostate cancer
patients. Tevrlex is designed to suppress testosterone rapidly without the initial
testosterone surge that agonists cause, with a potentially more favorable cardiovascular safety
profile. The FDA has granted clearance for a Phase IIb study on Tevrlex, adding a second
clinical catalyst for the company's near-term pipeline.
Now, of course, this is a super small-cap biotech stock, and those are some of the
riskiest in the market. This company has no approved products and no established revenue
streams. Clinical trials can fail at any stage. Any positive interim data does not guarantee
successful final results or regulatory approval. And of course, there are many other risks,
so you want to make sure that you're reading over the SEC filings and doing all your own
due diligence.
But anyways, bigger picture here, they are developing what could be one of the first
microneedle-delivered chemical chemotherapy approaches for basal cell carcinoma, the
single most common form of cancer in the United States. For anyone interested in clinical-stage
oncology companies, MDCX may be worth keeping an eye on and beginning your due diligence on.
Anyways, that caps off today's video. Have a great rest of your day. We'll see you next time.
